Collaborating Across the Continuum™: Managing Relapsing MS – A Focus on the Utility of CD20-Targeted B-Cell Therapy
Released On
November 30, 2022
Expires On
November 30, 2023
Media Type
Internet
Completion Time
75 minutes
Specialty
Neurology, Pharmacy
Topic(s)
Multiple Sclerosis, New Drugs
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Physicians’ Education Resource®, LLC. and The Consortium of Multiple Sclerosis Center
This activity is supported by an educational grant from Genentech, Inc.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Nurses — 1.25 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for community neurologists, MS specialists, specialty nurse practitioners, physician assistants, registered nurses, pharmacists, and other members of the MS care team.
Activity Overview
Following the success of anti-CD20 antibodies in the treatment of multiple sclerosis (MS), there has been a shift in understanding of its pathophysiology. B cells have been identified as playing a key role in triggering MS disease activity, although it remains unclear which intercepted B-cell function is most relevant in this context. These advances in understanding of the immune mechanisms have led to the development of many immunotherapeutic drugs that target B cells. For example, there have been successful trials for 4 anti-CD20 monoclonal antibodies in patients with MS, showing that B-cell depletion can be an effective treatment for the relapsing subtype. This activity will focus on developments in understanding the role of B cells in the pathogenesis of MS, emerging therapies, and strategies for developing personalized care to improve outcomes and quality of life for patients with relapsing MS (RMS).
Learning Objectives
- Upon completion of this activity, participants should be better able to:
-
- Describe the role of B cells in the pathogenesis of MS in order to better recognize potential targets for therapy
- Analyze clinical trial data for current and emerging anti-CD20 monoclonal antibody therapies in order to optimize treatment choices for appropriate patients with RMS
- Design individualized treatment plans for the optimal management of patients with RMS
Faculty
Stephen Krieger, MD, FAAN
Professor of Neurology
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Jacci Bainbridge, PharmD, FCCP
Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, CO
Denise Bruen, ANP-BC, MSN, MSCN
Adult Nurse Practitioner
Director of Clinical Operations, James Q. Miller MS Center
University of Virginia Medical Center
Charlottesville, VA
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Physicians' Education Resource®, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this knowledge-based activity (UAN # JA4008165-9999-22-040-H01-P) for 1.25 contact hours (.125 CEUs) of continuing pharmacy education credit.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Stephen Krieger, MD, FAAN
-
- Grant/Research Support: Biogen, BMS, Novartis, Sanofi
- Consultant: Biogen, EMD Serono, Genentech, Novartis, Octave, Genzyme/Sanofi, TG Therapeutics
- Speaker’s Bureau: (non-promotional speaking) Biogen, EMD Serono, Genentech
- Jacci Bainbridge, PharmD, FCCP
-
- Advisory Board: Novartis
- Denise Bruen, ANP-BC, MSN, MSCN
-
- Consultant: Biogen,BMS, EMD Serono, Janssen, Novartis, Sanofi, TG therapeutics
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an accredited continuing education activity disclose all financial relationships with any ineligible company within the past 24 months. It is the policy of the CMSC to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. CMSC seeks to ensure independence, objectivity, balance, and scientific rigor in all educational programs and to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in healthcare and not those of an ineligible company. For this activity, all relevant financial relationships have been mitigated.
The planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.